A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).

Registry ID

EUCTR2004-000462-13

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

TEVA Pharmaceutical Industries Ltd.

Start date

2004-07-12

Last update

2026-08-16

Conditions

• Relapsing-remitting multiple sclerosis (R-R MS)
• Subjects with Relapsing-Remitting Multiple Sclerosis.Subjects must have had at least one documented relapse within one year prior to screening visit

Summary

To evaluate the effect of a daily oral dose of 600 mg glatiramer acetate on MRI disease activity as measured by the total number of T1 gadolinium-enhancing lesions in subjects with relapsing-remitting multiple sclerosis.

Locations

• , , Hungary
• , , Italy

View on source registry